This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirozane, T. Articles by Sasayama, S. Search for Related Content PubMed PubMed Citation Articles by Hirozane, T. Articles by Sasayama, S.

(Circulation. 1995;91:386-392.)
© 1995 American Heart Association, Inc.

Articles

Experimental Graft Coronary Artery Disease in a Murine Heterotopic Cardiac Transplant Model

Toshiro Hirozane, MD; Akira Matsumori, MD; Yutaka Furukawa, MD; Shigetake Sasayama, MD

From the Third Division, Department of Internal Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan.

Correspondence to Akira Matsumori, MD, Third Division, Department of Internal Medicine, Faculty of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606 Japan.

Background The development of immunosuppressive therapy has brought about a remarkable decrease in the risk of acute cardiac allograft rejection; however, the major cause of patient death or retransplantation after the first postoperative year is coronary artery disease (CAD) in the graft. The pathogenesis and management of CAD are still not clearly established.

Methods and Results To make an animal model of CAD, we performed primary vascularized heterotopic cardiac transplantation using mice. Inbred strains, sharing major histocompatibility antigens but differing in minor antigens, were selected. DBA/2 mice (H-2^d) served as donors and B10.D2 mice (H-2^d) as recipients. Viability of the cardiac grafts was assessed by abdominal palpation. Eight of twelve cardiac allografts (67%) survived for 10 weeks after operation without any immunosuppressive therapy. Allografts rejected within 4 weeks showed acute rejection histologically, whereas allografts surviving more than 4 weeks displayed intimal hyperplasia in the coronary arteries, together with interstitial and perivascular fibrosis. The severity of intimal thickening in the graft coronary artery was then assessed by point counting. In allografts surviving for 70 days, intima comprised approximately 42% of the graft arterial wall, whereas in DBA/2 and B10.D2 syngeneic grafts, it comprised approximately 13%. A significant difference in percentage was observed between the intima area of allografts and that of syngrafts (P<.01, ANOVA). Long-term oral administration of cyclosporine at a dose of 40 mg/kg per day decreased the intima area to 34% (P<.05 versus nontreated allografts, ANOVA); however, this dose did not affect the incidence of arterial lesions.

Conclusions The histopathological features of DBA/2 allografts surviving for 10 weeks in B10.D2 recipient mice mimicked those in human CAD. Using this animal model, the beneficial effect of low-dose cyclosporine therapy on CAD was demonstrated, although this effect seemed to be limited. This DBA/2-B10.D2 mouse heterotopic cardiac transplant model provides valuable results for future studies of the disease.

Key Words: coronary disease • transplantation • rejection

This article has been cited by other articles:

				S. J. Kim and J. S. Gill H-Y Incompatibility Predicts Short-Term Outcomes for Kidney Transplant Recipients J. Am. Soc. Nephrol., September 1, 2009; 20(9): 2025 - 2033. [Abstract] [Full Text] [PDF]

				A. Saiura, M. Sata, K.-i. Hiasa, S. Kitamoto, M. Washida, K. Egashira, R. Nagai, and M. Makuuchi Antimonocyte Chemoattractant Protein-1 Gene Therapy Attenuates Graft Vasculopathy Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1886 - 1890. [Abstract] [Full Text] [PDF]

				T. Hattori, H. Shimokawa, M. Higashi, J. Hiroki, Y. Mukai, K. Kaibuchi, and A. Takeshita Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice Circ. Res., January 9, 2004; 94(1): 46 - 52. [Abstract] [Full Text] [PDF]

				A. Izawa, J.-i. Suzuki, W. Takahashi, J. Amano, and M. Isobe Tranilast Inhibits Cardiac Allograft Vasculopathy in Association With p21Waf1/Cip1 Expression on Neointimal Cells in Murine Cardiac Transplantation Model Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1172 - 1178. [Abstract] [Full Text] [PDF]

				M.-W. Hwang, A. Matsumori, Y. Furukawa, K. Ono, M. Okada, A. Iwasaki, M. Hara, and S. Sasayama FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation Circulation, September 21, 1999; 100(12): 1322 - 1329. [Abstract] [Full Text] [PDF]

				P. Carmeliet, L. Moons, and D. Collen Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis Cardiovasc Res, July 1, 1998; 39(1): 8 - 33. [Abstract] [Full Text] [PDF]

				A. Raisanen-Sokolowski, T. Glysing-Jensen, P. L. Mottram, and M. E Russell Sustained Anti-CD4/CD8 Treatment Blocks Inflammatory Activation and Intimal Thickening in Mouse Heart Allografts Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 2115 - 2122. [Abstract] [Full Text]

				Y. Furukawa, A. Matsumori, T. Hirozane, and S. Sasayama Angiotensin II Receptor Antagonist TCV-116 Reduces Graft Coronary Artery Disease and Preserves Graft Status in a Murine Model : A Comparative Study With Captopril Circulation, January 15, 1996; 93(2): 333 - 339. [Abstract] [Full Text]